TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00659425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
Study: NCT03059758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
Study: NCT02056977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration
Description: Individualized PEEP according to PEEP titration monitored by EIT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
Study: NCT00846235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%
Description: moisturising cream twice daily three weeks
Study: NCT04850001

Intervention type: DRUG
Intervention: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Description: All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
Study: NCT00806351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Anidulafungin
Description: Subjects in this arm will receive active anidulafungin and placebo caspofungin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Caspofungin
Description: Subjects in this arm will receive active caspofungin and placebo anidulafungin
Study: NCT04899154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool sampling
Description: Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool sampling
Description: Participants will provide one stool sample at inclusion
Study: NCT01972568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 milligram (mg)
Description: Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
Study: NCT04111198

Intervention type: RADIATION
Intervention: Cardiac MRI
Description: Cardiac MRI
Study: NCT04340362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-147
Description: Tablets for oral administration.
Study: NCT04270734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG
Description: Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIRS
Description: Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
Study: NCT02767219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.

Intervention type: DRUG
Group type: OTHER
Intervention: 5-fluorouracil
Description: Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
Study: NCT00811057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 Magnesium Sulfate
Description: Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
Study: NCT06409988

Intervention type: OTHER
Intervention: Safe discharge
Description: There was no specific intervention, we only aimed to see if those admitted patients could have been safely dicharged from the emergency department.
Study: NCT00659425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
Study: NCT01752803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: mix probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00567515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure LAA Exclusion System
Description: Placement of clip of LAA.
Study: NCT03319589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
Study: NCT04039971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: Surgical techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: Surgical techniques
Study: NCT01126307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: 80 mg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tid
Study: NCT00612001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Study: NCT00241423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
Study: NCT02178917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback therapy

Intervention type: OTHER
Group type: OTHER
Intervention: No neurofeedback therapy
Study: NCT00337818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
Study: NCT03128658

Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastography
Description: Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Computational model
Description: The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
Study: NCT01199237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Study: NCT05391724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX001
Description: single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
Study: NCT01876654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruMatch® patient specific cutting guide
Study: NCT00420186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-690514
Description: Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
Study: NCT01623349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 and Olaparib
Description: Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 and Olaparib
Description: Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
Study: NCT01694628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLIMB (COPD Lifestyle, Mood, and Behavior)
Description: Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
Study: NCT01883323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: i.v., 25mg/m2 per day for 5 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes
Description: i.v., 1x10\^10 - 1.6x10\^11 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-Dose Interleukin
Description: i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
Study: NCT03112902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
Study: NCT01814800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RI-002
Description: Immune Globulin Intravenous (IGIV)
Study: NCT02703740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid dermal filler with lidocaine 0.3%
Description: injection in labial fold of a dermal filler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid dermal filler with lidocaine 0.3%
Description: injection in labial fold of a dermal filler
Study: NCT02083991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon
Study: NCT04917835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLADUO(PX1000)
Description: Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
Study: NCT01060735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
Study: NCT02130427

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan
Description: Weekly 3D/4D CT scan
Study: NCT02202031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced Respiration
Description: Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
Study: NCT03326219

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clarivein
Description: The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
Study: NCT04369430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKST4290
Description: Oral AKST4290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study: NCT01589068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
Study: NCT00819624

Intervention type: OTHER
Group type: OTHER
Intervention: Interactive Voice Response System (IVRS)
Description: Telephone based system

Intervention type: OTHER
Group type: OTHER
Intervention: Personal Digital Assisstant (PDA)
Description: Electronic Hand Held diary
Study: NCT01606592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Panic Control Treatment (PCT)
Description: Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Panic Control Treatment (PCT)
Description: Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Description: Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Description: Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting-list
Description: Sparse telephone contact during 12 weeks, then re-randomization
Study: NCT00798213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemtuzumab ozogamicin
Description: Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.